-
Canceled13/08/2026
-
Today11/09/2026
Utilities
- indicates text translated automatically in your browsing language
Cancellation of the open house procedure Drug rebate agreements Denosumab, ATC M05BX04
The open house drug rebate agreement for denosumab, ATC M05BX04, will be terminated with immediate effect from 30.09.2026. All existing contracts will be terminated on 30.09.2026. The conclusion of contracts is no longer possible under this Open House procedure.
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.